← Back to Vital Edge Science
← Back to Vital Edge Science Compound Comparison Tool

How are these compounds
scientifically different?

Compare mechanisms, targets, research profiles and pharmacokinetics for up to 4 compounds side by side. This maps what is scientifically known — it does not tell you which compound to choose.

This is a scientific comparison, not a recommendation. It does not answer "which should I take?" — for potential combination-specific considerations, see the Interaction Checker; for regulatory/clinical-development history, see the Research Status Explorer.

Tirzepatide × Retatrutide × 2 of 4 selected View comparison

Tirzepatide

Dual incretin receptor agonist

Remove
VS

Retatrutide

Triple receptor agonist

Remove

Target & Mechanism Comparison

Primary molecular targets for each selected compound, drawn directly from each compound's structured scientific record. Not every compound has a single conventional receptor target — where that's the case, its differentiating mechanism is noted below instead.

← Scroll to see all compounds →

Target TirzepatideRetatrutide
✓ ✓
✓ ✓
— ✓

Pathway Map

This is a schematic, not a claim that every step shown has been directly demonstrated for each compound. The receptor immediately after each compound is its direct, structurally-confirmed target; anything shown beyond that receptor represents the broader documented signalling axis for that receptor family in general, not a compound-specific downstream finding.

Direct targets only — no downstream biology implied for this group.

Tirzepatide → GLP-1R GIPR
Retatrutide → GLP-1R GIPR GCGR

What These Compounds Share

Shared direct targets (all selected compounds)
GIPRGLP-1R
Shared research line

All selected compounds are catalogued under Metabolic.

Shared pathway tags
GIPRGLP-1RIncretinMetabolic
Shared research areas
Type 2 diabetesObesityMetabolic disease

Key Differences

Tirzepatide Shares its entire target profile with at least one other compound here — no single receptor sets it apart on its own. Combines GIP and GLP-1 receptor agonism without the glucagon-receptor component of retatrutide.
Retatrutide Also activates GCGR — on top of the GIPR and GLP-1R it shares with the rest of this selection. Only current Vital Edge compound combining GLP-1, GIP and glucagon receptor agonism.

Compound Detail

Tirzepatide
What is it?
A lab-made peptide that mimics two natural gut hormones involved in blood sugar and appetite control.
What are people researching/using it for?
Approved and studied for type 2 diabetes and weight management.
Other uses being trialed
Sleep apnea linked to obesityHeart-related metabolic research
Worth knowing
Approved for specific branded products/indications only -- research in additional populations and combinations is ongoing.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
Activates GIP and GLP-1 receptors, influencing glucose-dependent insulin secretion, glucagon regulation, appetite and energy intake.
Synthetic acylated peptide · Synthetic analogue
Primary Targets & Biological System
Incretin / metabolic signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
Activates both GIP and GLP-1 receptors -- the two incretin hormone receptors that respond when nutrients enter the gut, prompting the pancreas to release insulin in a glucose-dependent way (more when blood sugar is high, less when it isn't) and slowing gastric emptying, which contributes to reduced appetite. Combining both receptors' activity, rather than GLP-1R alone, is the specific mechanistic distinction from single-receptor GLP-1 agonists like semaglutide, and is what regulatory approvals for tirzepatide-based products have been built on for type 2 diabetes and weight management.
Research Areas
Type 2 diabetesObesityGlucose regulationEnergy intakeMetabolic disease
Research Profile
Human administration: Extensive Preclinical: Available
Pharmacokinetics
Approximately 5 days
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Combines GIP and GLP-1 receptor agonism without the glucagon-receptor component of retatrutide.
Considerations
Research Limitations
Approved for specific branded products/indications only -- research in additional populations and combinations is ongoing.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Alcohol and substance use
Dual GIP/GLP-1 agonism is being studied for effects on alcohol consumption, extending from the larger evidence base for GLP-1-only agonists like semaglutide -- early-stage relative to that body of work.
Fatty liver disease (MASLD/NAFLD)
Liver fat reduction has been an active secondary research area in tirzepatide metabolic trials.
Availability & Sources
Current Vital Edge Testing
Batch 1 · tested Oct 2026 · 99.878% purity, 35.12mg content Purity/ID report
Available As (Vital Edge Science)
Tirzepatide · A$179.95 A$199.95
Browse products →

Source review pending for this compound — no citation on file yet.

Retatrutide
What is it?
A lab-made peptide designed to activate three metabolic hormone receptors at once (GLP-1, GIP and glucagon) to help the body manage blood sugar, appetite and energy use.
What are people researching/using it for?
Mainly researched for weight loss and improving blood sugar control.
Other uses being trialed
Type 2 diabetesFatty liver disease
Worth knowing
Registrational trials are ongoing; long-term outcome data beyond current trial durations is not yet available.

Simplified for general understanding. Switch to "Full science" above for the complete research-level detail, targets, pharmacokinetics and sources.

Identity
What is it?
A single peptide engineered to activate GIP, GLP-1 and glucagon receptors simultaneously.
Synthetic acylated peptide · Synthetic analogue
Also known as: LY3437943
Primary Targets & Biological System
Incretin / metabolic / glucagon signalling

Tap a target above for a plain-language explanation.

Mechanism & Research Profile
How does it work?
A single peptide engineered to activate three receptors at once: GLP-1R and GIPR (the two incretin receptors that respond to nutrient intake, central to how the body regulates insulin secretion and appetite) plus GCGR, the glucagon receptor -- usually associated with raising blood sugar and increasing energy expenditure rather than lowering it. Combining incretin agonism with glucagon-receptor agonism is the specific pharmacological rationale distinguishing retatrutide from single- or dual-receptor agonists: in Phase 2 human trials this combination was associated with reductions in body weight and improved glucose regulation. The relative contribution of the GCGR component specifically, versus the shared GLP-1R/GIPR activity, has not been isolated in human studies to date.
Research Areas
ObesityEnergy balanceGlucose metabolismType 2 diabetesMetabolic diseaseHepatic/metabolic outcomes
Research Profile
Human administration: Extensive Human observational: Available Preclinical: Available
Pharmacokinetics
Approximately 6 days
Research Routes
Subcutaneous (descriptive only — not administration or dosing guidance)
Key Differentiator
Only current Vital Edge compound combining GLP-1, GIP and glucagon receptor agonism.
Considerations
Research Limitations
Registrational trials are ongoing; long-term outcome data beyond current trial durations is not yet available.
Experimental / Off-Label Research

Not an approved or established use. These are active or emerging research directions found in the literature, shown for informational context only — not a claim that this compound is approved, effective, or safe for these purposes.

Fatty liver disease (MASLD/NAFLD)
Reductions in liver fat have been reported as a secondary finding in retatrutide obesity trials -- an active research direction, not a separate approved indication.
Obstructive sleep apnea
Investigated as a downstream effect of significant weight loss rather than a direct mechanism of its own; research in this specific population is ongoing.
Availability & Sources
Current Vital Edge Testing
Batch 2 (30mg) · tested Oct 2026 · 99.834% purity, 33.22mg content Purity/ID report
Batch 1 (30mg) Purity/ID report
Available As (Vital Edge Science)
Retatrutide — 10mg · A$109.95 A$119.95 Retatrutide — 30mg · A$299.95 A$319.95
Browse products →
View Research Sources (1) →
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine, 2023 · Human Human · Phase 2 obesity trial participants · Subcutaneous · DOI 10.1056/NEJMoa2301972

Supports GIP/GLP-1/glucagon receptor agonism and the ~6-day half-life used on this record.

Supports: primary_targets, human_half_life, mechanism_summary

Common Research Comparisons

Frequently studied groupings — not recommendations.

Browse more compounds

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Choose a compound

Metabolic

5-Amino-1MQ

NNMT inhibitor

NNMTNicotinamideNAD MetabolismSmall Molecule
Rebuild

BPC-157

Gastric pentadecapeptide

GI ResearchTissue RepairAngiogenesisNO-associated
Metabolic

Cagrilintide

Long-acting amylin analogue

AmylinSatietyAppetiteMetabolic
Peak

CJC-1295

Modified GHRH analogue

GHRHRModified GRFGHIGF-1
Neuro

DSIP

Neuropeptide

Sleep ResearchNeuropeptideNeuroendocrineCNS
Rebuild

Epithalon

Synthetic tetrapeptide

Telomere ResearchTelomeraseCellular AgeingTetrapeptide
Rebuild

GHK-Cu

Copper-binding tripeptide

Copper PeptideECMFibroblastCollagen
Peak

GHRP-2

GH-releasing peptide / GH secretagogue

GHSR1aGhrelinGH SecretagogueAppetite
Rebuild

Glutathione

Endogenous antioxidant tripeptide

GSHRedoxAntioxidantOxidative Stress
Metabolic

HCG

Glycoprotein hormone

LHCGRReproductive AxisGonadalEndocrine
Reference

IGF-1 LR3

IGF-1 receptor agonist (engineered analogue)

IGF1RGrowth FactorPI3K/AKTRAS/MAPK
Peak

Ipamorelin

GH secretagogue

GHSR1aGH SecretagogueGhrelin PathwayGH
Enhance

Kisspeptin-10

Kisspeptin fragment

KISS1RGnRHLHFSH
Rebuild

KPV

α-MSH-derived tripeptide

KPVα-MSH FragmentInflammationIL-1-associated
Enhance

Melanotan I

α-MSH analogue

MC1RMelanocortinPigmentationα-MSH Analogue
Enhance

Melanotan II

Cyclic melanocortin agonist

MelanocortinMC ReceptorsPigmentationCyclic Peptide
Metabolic

MOTS-c

Mitochondrial-derived peptide

MitochondrialAMPK-associatedMetabolicExercise Biology
Metabolic

NAD+

Cellular redox cofactor

NAD+RedoxCellular EnergySirtuins
Enhance

PT-141

Cyclic melanocortin receptor agonist

MelanocortinMC4R-associatedCNSSexual Response
Metabolic

Retatrutide

Triple receptor agonist

GLP-1RGIPRGCGRIncretin
Reference

rHGH (Somatropin)

Growth hormone receptor agonist

GHRIGF-1Growth HormonePituitary-independent
Neuro

Selank

Synthetic tuftsin analogue

Tuftsin AnalogueCNSStress ResearchNeurotransmitter Research
Metabolic

Semaglutide

GLP-1 receptor agonist

GLP-1RIncretinMetabolicGlucose
Neuro

Semax

Synthetic ACTH-fragment analogue

ACTH FragmentNeurotrophinBDNF-associatedCNS
Peak

Sermorelin

GHRH fragment analogue

GHRHRGHRH(1-29)PituitaryGH
Rebuild

SS-31

Mitochondria-targeting tetrapeptide

MitochondriaCardiolipinInner Mitochondrial MembraneBioenergetics
Peak

Tesamorelin

Stabilised GHRH analogue

GHRHRGHIGF-1Pituitary
Rebuild

Thymosin Alpha-1

Thymic peptide

ImmuneT CellsTLR-associatedInnate Immunity
Rebuild

Thymosin Beta-4 (TB-4)

Thymosin Beta-4

Thymosin Beta-4Actin BiologyCell MigrationRepair Research
Metabolic

Tirzepatide

Dual incretin receptor agonist

GIPRGLP-1RDual AgonistIncretin

Simplified for general understanding — see this compound's "How does it work?" section for the full research-level description.